Rivoceranib

Generic Name: Rivoceranib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₃N_₅O

CAS Number: 811803-05-1

Unique Ingredient Identifier: 5S371K6132

Background: Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

Indication: 本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer

Phase 2

Active, not recruiting

Conditions: Gastric Cancer Stage IV

Interventions: Drug: sintilimab
Drug: apatinib
Drug: S1
Drug: Nab paclitaxel

First Posted Date: 2020-02-13

Last Posted Date: 2023-07-06

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 47

Registration Number: NCT04267549

Locations: 🇨🇳
Department of Gastric Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Clinical Study of Apatinib Combined With Temozolomide in the Treatment of Uncontrolled or Repeated High-grade Gliomas

Phase 2

Conditions: High-grade Gliomas

Interventions: Drug: Apatinib

First Posted Date: 2020-02-05

Last Posted Date: 2020-02-05

Lead Sponsor: WuHui

Target Recruit Count: 40

Registration Number: NCT04253873

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer

Phase 2

Conditions: Uterine Cancer
Advanced Non Small Cell Lung Cancer
Soft Tissue Sarcoma

Interventions: Drug: PD-1 inhibitor
Drug: Apatinib

First Posted Date: 2020-01-27

Last Posted Date: 2020-01-27

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 120

Registration Number: NCT04239443

Locations: 🇨🇳
Hunan cancer Hospital, Changsha, Hunan, China

Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas

Recruiting

Conditions: Recurrent Glioma

Interventions: Drug: Apatinib

First Posted Date: 2020-01-02

Last Posted Date: 2021-02-08

Lead Sponsor: The First Affiliated Hospital of Zhengzhou University

Target Recruit Count: 600

Registration Number: NCT04216550

Locations: 🇨🇳
Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers

Phase 2

Conditions: Apatinib
Thyroid
Metastasis

Interventions: Drug: Apatinib

First Posted Date: 2019-11-27

Last Posted Date: 2019-11-27

Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Target Recruit Count: 10

Registration Number: NCT04180007

Locations: 🇨🇳
Nanjing First Hospital, Nanjing, Jingsu, China

Effect and Safety of Apatinib on Radiation-Induced Brain Injury

Phase 2

Conditions: Radiation Injuries

Interventions: Drug: Apatinib

First Posted Date: 2019-11-05

Last Posted Date: 2019-11-05

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 36

Registration Number: NCT04152681

Locations: 🇨🇳
Yamei Tang, Guanzhou, Guangdong, China

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

Phase 1

Conditions: Lung Diseases
Neoplasms
Respiratory Tract Diseases
Non-small-cell Lung Cancer
Thoracic Neoplasms

Interventions: Drug: Apatinib
Drug: SHR-1210

First Posted Date: 2019-10-21

Last Posted Date: 2019-10-21

Lead Sponsor: Sichuan Cancer Hospital and Research Institute

Target Recruit Count: 20

Registration Number: NCT04133337

Locations: 🇨🇳
Sichuan Cancer Hospital, Chengdu, Sichuan, China

Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma

Phase 2

Conditions: Sarcoma

Interventions: Drug: Camrelizumab,
Drug: Apatinib

First Posted Date: 2019-10-15

Last Posted Date: 2019-10-15

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 80

Registration Number: NCT04126993

Locations: 🇨🇳
Tianjin Medical University Cancer Hospital & Institute, Tianjin, Tianjin, China

Study of the Apatinib Combine With POF Versus POF in Gastric Cancer

Phase 2

Conditions: Gastric Adenocarcinoma
Advanced Cancer

Interventions: Drug: Apatinib
Drug: POF

First Posted Date: 2019-10-09

Last Posted Date: 2019-10-09

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 116

Registration Number: NCT04121039

Locations: 🇨🇳
Rongbo Lin, Fuzhou, Fujian, China

A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

Phase 2

Terminated

Conditions: Adenoid Cystic Carcinoma

Interventions: Drug: Rivoceranib

First Posted Date: 2019-10-08

Last Posted Date: 2024-06-24

Lead Sponsor: Elevar Therapeutics

Target Recruit Count: 80

Registration Number: NCT04119453

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Gyeonggi-do, Korea, Republic of
🇰🇷
National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷
Asan Medical Center, Seoul, Gyeonggi, Korea, Republic of

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy